Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer

Carlos L. Arteaga, Fadlo Khuri, Geoffrey Krystal, Said Sebti

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


Most cellular proto-oncogenes encode proteins that participate in signaling pathways by which cells receive and execute instructions that lead to mitogenesis, differentiation, lineage determination, cell migration, extracellular matrix production, and apoptosis, among others. These proto-oncogene protein products include transmembrane receptor tyrosine kinases and receptor substrates, serine/threonine kinases, receptor adaptor molecules, low-molecular-weight GTPases, and transcription factors that, when overexpressed or mutationally activated, can lead to cell transformation and tumor progression. The large number of oncogenic protein tyrosine kinases plus the rare presence of phosphotyrosine in nontransformed cells argue persuasively that tyrosine phosphorylation and activation of signaling molecules downstream from receptor tyrosine kinases are critical events in growth control and transformation and are, therefore, rational targets for anticancer molecular therapies. We will review some of the more recent treatment strategies in non-small cell and small cell lung cancer targeted to dysregulated signaling pathways that are causally associated with tumor maintenance and progression.

Original languageEnglish (US)
Pages (from-to)15-26
Number of pages12
JournalSeminars in oncology
Issue number1 SUPPL. 4
StatePublished - 2002

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer'. Together they form a unique fingerprint.

Cite this